Glycine Antagonist in Neuroprotection-2 "GAIN 2"

Completed

Phase 2 Results

Summary of Purpose

To test the safety and pharmacokinetics of GV150526 in patients with a clinical diagnosis of acute ischemic stroke managed in North American centers.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 12 August 2008.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • Glaxo Wellcome, Research Triangle, NC

Trial Design

Randomized (2:1), double-blind, and placebo controlled involving 33 centers. GAIN 2 (GLYA2005; United States and Canada) was designed to further assess the safety of the highest dose tolerated in GAIN 1.

Contacts

Not available